{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:52:01Z","timestamp":1794005521436,"version":"4.8.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["2015-0524"],"award-info":[{"award-number":["2015-0524"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["2015-0564"],"award-info":[{"award-number":["2015-0564"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["ERA-NET ER-2017-2364981"],"award-info":[{"award-number":["ERA-NET ER-2017-2364981"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["PHC-03-2015\/667837-2"],"award-info":[{"award-number":["PHC-03-2015\/667837-2"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.atherosclerosis.2018.06.859","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T09:46:39Z","timestamp":1538127999000},"page":"483-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"special_numbering":"C","title":["Familial hypercholesterolemia treatments: Guidelines and new therapies"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7938","authenticated-orcid":false,"given":"Frederick J.","family":"Raal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib3","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/eurheartj\/ehv602","article-title":"Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death","volume":"37","author":"Krogh","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib5","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib6","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1373\/clinchem.2004.038026","article-title":"Lipid disorders and mutations in the APOB gene","volume":"50","author":"Whitfield","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib7","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jacl.2016.09.009","article-title":"Familial defective apolipoprotein B-100: a review","volume":"10","author":"Andersen","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1060458","article-title":"Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein","volume":"292","author":"Garcia","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gene.2014.09.020","article-title":"The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification","volume":"555","author":"Fellin","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1373\/clinchem.2014.231365","article-title":"Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries","volume":"61","author":"Futema","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia-epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2014.06.005","article-title":"Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutation","volume":"236","author":"Mabuchi","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib14","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)15467-6","article-title":"Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia","volume":"363","author":"Wiegman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib17","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0735-1097(02)02593-7","article-title":"Early statin therapy restores endothelial function in children with familial hypercholesterolemia","volume":"40","author":"de Jongh","year":"2002","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.atherosclerosis.2014.05.917","article-title":"Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review","volume":"235","author":"Narverud","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.114.301430","article-title":"Carotid intima-media thickness in children with familial hypercholesterolemia","volume":"114","author":"Kusters","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","article-title":"2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","volume":"39","author":"Landmesser","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib21","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish familial hypercholesterolemia cohort study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0021-9150(93)90260-2","article-title":"Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia","volume":"103","author":"Feher","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-9150(97)00168-8","article-title":"Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia","volume":"135","author":"Raal","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(99)00435-9","article-title":"Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia","volume":"150","author":"Raal","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib26","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2007.06.028","article-title":"A\u00a0dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia","volume":"197","author":"Marais","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib27","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1161\/ATVBAHA.107.145151","article-title":"A\u00a0systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia","volume":"27","author":"Avis","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacl.2015.07.011","article-title":"Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study","volume":"9","author":"Braamskamp","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/CIRCULATIONAHA.116.025158","article-title":"Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (hypercholesterolemia in children and adolescents taking rosuvastatin open label)","volume":"136","author":"Braamskamp","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib30","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jacc.2017.06.058","article-title":"Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations","volume":"70","author":"Stein","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpeds.2015.05.006","article-title":"Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk","volume":"167","author":"Braamskamp","year":"2015","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib32","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5551\/jat.42242","article-title":"Efficacy and safety of pitavastatin in children and adolescents with familial hypercholesterolemia in Japan and europe","volume":"25","author":"Harada-Shiba","year":"2018","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacl.2017.12.014","article-title":"Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy","volume":"12","author":"Galema-Boers","year":"2018","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib35","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2011.02.007","article-title":"Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia","volume":"216","author":"Nenseter","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib37","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib38","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib39","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2010.02.003","article-title":"Pleiotropic effects of ezetimibe: do they really exist?","volume":"633","author":"Kalogirou","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib41","first-page":"514","article-title":"Efficacy and safety of long-term ezetimibe\/simvastatin treatment in patients with familial hypercholesterolemia","volume":"29","author":"Avellone","year":"2010","journal-title":"Int. Angiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2006.10.036","article-title":"Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients","volume":"194","author":"Pisciotta","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib44","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jacc.2008.09.002","article-title":"Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia","volume":"52","author":"van der Graaf","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11883-010-0123-6","article-title":"The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis","volume":"12","author":"Davignon","year":"2010","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib48","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib49","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib50","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib52","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib54","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (Low-Density lipoprotein receptor): implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib55","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.atherosclerosis.2016.07.374","article-title":"Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG)","volume":"252","author":"Stein","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib56","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.atherosclerosis.2016.07.221","article-title":"Cardiovascular event rates in homozygous familial hypercholesterolemia (HOFH): trialassessing long-term use of pcsk9 inhibition in subjects with genetic LDL disorders (TAUSSIG) study interim results","volume":"252","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib57","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib58","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib59","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib60","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib61","article-title":"Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia","volume":"11","author":"Defesche","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib62","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2017.12.008","article-title":"Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia","volume":"12","author":"Hartgers","year":"2018","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/VHRM.S130338","article-title":"Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives","volume":"13","author":"Catapano","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","article-title":"Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B","volume":"76","author":"Crooke","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib65","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib66","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib67","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib68","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib69","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib70","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40256-014-0077-0","article-title":"Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials","volume":"14","author":"Li","year":"2014","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2014.12.006","article-title":"Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"9","author":"Panta","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib72","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib73","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jacl.2014.08.002","article-title":"Liver histology during Mipomersen therapy for severe hypercholesterolemia","volume":"8","author":"Hashemi","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib74","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib75","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jacl.2013.02.004","article-title":"Emerging LDL therapies: mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia","volume":"7","author":"Toth","year":"2013","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib76","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCRESAHA.116.304637","article-title":"Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein","volume":"116","author":"Hooper","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib78","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jacl.2013.03.003","article-title":"Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors","volume":"7","author":"Goldberg","year":"2013","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib79","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14656566.2017.1340941","article-title":"Lomitapide for the treatment of hypercholesterolemia","volume":"18","author":"Berberich","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib80","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib81","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.numecd.2015.11.001","article-title":"Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: the Italian cohort","volume":"26","author":"Averna","year":"2016","journal-title":"Nutr. Metabol. Cardiovasc. Dis. : Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/phar.1351","article-title":"Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia","volume":"34","author":"Tuteja","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib83","unstructured":"http:\/\/www.aegerion.com\/Collateral\/Documents\/English-US\/012187_JuxtapidPI_8%205x11_FIN.pdf."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib85","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib87","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacl.2016.10.007","article-title":"JCL roundtable: risk evaluation and mitigation strategy","volume":"10","author":"Brown","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib88","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefanutti","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib89","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/petr.12763","article-title":"Liver transplantation for homozygote familial hypercholesterolemia: the only curative treatment","volume":"20","author":"Alim","year":"2016","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib90","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/petr.12562","article-title":"Liver transplantation as a definitive treatment for familial hypercholesterolemia: a series of 36 cases","volume":"19","author":"Mansoorian","year":"2015","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib91","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/imj.12444","article-title":"Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies","volume":"44","author":"Page","year":"2014","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib92","first-page":"138","article-title":"Progressive aortic stenosis in homozygous familial hypercholesterolemia after liver transplant","author":"Greco","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib93","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12265-011-9311-1","article-title":"Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively","volume":"5","author":"Ibrahim","year":"2012","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib94","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A\u00a0highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib95","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib96","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib97","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib98","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib99","unstructured":"http:\/\/globenewswire.com\/news-release\/2018\/03\/07\/1417477\/0\/en\/Esperion-Announces-Positive-Top-Line-Results-from-First-Pivotal-Phase-3-Study-of-Bempedoic-Acid.html."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-016-0579-0","article-title":"Recent developments in gene therapy for homozygous familial hypercholesterolemia","volume":"18","author":"Ajufo","year":"2016","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib101","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jacl.2016.08.002","article-title":"Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients","volume":"10","author":"Stein","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib102","unstructured":"https:\/\/globenewswire.com\/news-release\/2017\/06\/28\/1031562\/0\/en\/Gemphire-Announces-Top-Line-Data-from-COBALT-1-Phase-2b-Clinical-Trial-in-HoFH-Patients.html."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib103","unstructured":"https:\/\/globenewswire.com\/news-release\/2017\/08\/07\/1080946\/0\/en\/Gemphire-Announces-Top-Line-Data-from-ROYAL-1-Phase-2b-Clinical-Trial-in-Hypercholesterolemic-Patients.html."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib104","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1515\/CCLM.2008.135","article-title":"Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing","volume":"46","author":"Starr","year":"2008","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib106","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2017-312706","article-title":"Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia","author":"Mundal","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib107","series-title":"Promoting Cardiovascular Health in the Developing World: a Critical Challenge to Achieve Global Health","author":"Institute of Medicine","year":"2010"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib108","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2017.03.021","article-title":"Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease","volume":"260","author":"Li","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib109","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.859_bib110","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1365-2362.1998.00399.x","article-title":"Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects","volume":"28","author":"Tonstad","year":"1998","journal-title":"Eur. J. Clin. Invest."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018311717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018311717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:38:15Z","timestamp":1758155895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018311717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":110,"alternative-id":["S0021915018311717"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.859","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial hypercholesterolemia treatments: Guidelines and new therapies","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}